As of close of business last night, Iovance Biotherapeutics Inc’s stock clocked out at $15.70, down -5.54% from its previous closing price of $16.62. In other words, the price has decreased by -$0.92 from its previous closing price. On the day, 11422764 shares were traded. IOVA stock price reached its highest trading level at $17.14 during the session, while it also had its lowest trading level at $15.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
To gain a deeper understanding of IOVA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.70 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Buy rating and assigned the stock a target price of $12.
On September 18, 2023, Barclays reiterated its Overweight rating and also upped its target price recommendation from $40 to $18.
Wells Fargo Upgraded its Equal Weight to Overweight on May 30, 2023, whereas the target price for the stock was revised from $11 to $17.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 20 ’24 when Rothbaum Wayne P. bought 5,000,000 shares for $9.15 per share. The transaction valued at 45,750,000 led to the insider holds 28,067,333 shares of the business.
MCPEAK MERRILL A bought 250,000 shares of IOVA for $2,287,500 on Feb 20 ’24. The Director now owns 320,150 shares after completing the transaction at $9.15 per share. On Feb 20 ’24, another insider, Dukes Iain D., who serves as the Director of the company, bought 32,000 shares for $9.15 each. As a result, the insider paid 292,800 and bolstered with 54,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 4.39B and an Enterprise Value of 4.18B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3685.01 while its Price-to-Book (P/B) ratio in mrq is 6.88. Its current Enterprise Value per Revenue stands at 3.52k whereas that against EBITDA is -9.78.
Stock Price History:
Over the past 52 weeks, IOVA has reached a high of $18.33, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is 10.61, while the 200-Day Moving Average is calculated to be 7.34.
Shares Statistics:
It appears that IOVA traded 10.66M shares on average per day over the past three months and 11.46M shares per day over the past ten days. A total of 256.14M shares are outstanding, with a floating share count of 214.70M. Insiders hold about 23.13% of the company’s shares, while institutions hold 67.26% stake in the company. Shares short for IOVA as of Feb 15, 2024 were 42.98M with a Short Ratio of 4.03, compared to 43.27M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 16.79% and a Short% of Float of 18.26%.
Earnings Estimates
As of right now, 11 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of -$0.32 and a low estimate of -$0.5, while EPS last year was -$0.5. The consensus estimate for the next quarter is -$0.35, with high estimates of -$0.15 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$0.47 and -$1.8 for the fiscal current year, implying an average EPS of -$1.32. EPS for the following year is -$0.8, with 11 analysts recommending between $0.34 and -$1.58.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $2.22M. It ranges from a high estimate of $6M to a low estimate of $500k. As of the current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $200k, an estimated increase of 1,010.00% from the year-ago figure. For the next quarter, 11 analysts are estimating revenue of $27.46M, an increase of 11,437.80% over than the figure of $1,010.00% in the same quarter last year. There is a high estimate of $60.6M for the next quarter, whereas the lowest estimate is $5.2M.
A total of 12 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $425.9M, while the lowest revenue estimate was $33.2M, resulting in an average revenue estimate of $172.75M. In the same quarter a year ago, actual revenue was $1.19M, up 14,429.00% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $378.15M in the next fiscal year. The high estimate is $603.28M and the low estimate is $130.5M. The average revenue growth estimate for next year is up 118.90% from the average revenue estimate for this year.
